Article ID Journal Published Year Pages File Type
3281441 Clinical Gastroenterology and Hepatology 2016 33 Pages PDF
Abstract
Almost two-thirds of patients with CD refractory to at least 1 anti-TNF agent receive clinical benefit from ustekinumab therapy, not requiring steroids for up to 12 months afterward. While awaiting results from ongoing trials, ustekinumab can be considered for use in these patients.
Related Topics
Health Sciences Medicine and Dentistry Gastroenterology
Authors
, , , , , , , , , , , , , , ,